SGLT2 inhibitor benefits cardiac patients without diabetes: study
Research suggests gliflozins may do more than lower glucose
26th November 2019
By Kemal Atlay
Patients with heart failure who don’t have diabetes benefit from being prescribed dapagliflozin as much as those with the disease, suggests a ground-breaking study.